How can digital help us to become more actively involved in our own health? Disease Mapping through Health Apps for example collecting data that can help pharma understand our diseases better, whilst we get to self manage to a better level!

Should a better understanding of patient experience be the driver behind disease awareness? The question could be… Is it the driver behind disease awareness, which then helps to improve communications, and also, to develop a level of trust between pharma and patients?

October is Health Literacy Awareness Month and an issue that as patients we feel to be a very important issue to address. It is great to be able to debate it, and hopefully, to help build a bridge between pharma and patients by creating possible solutions.

Thinking about medical literature, jargons and general language, and how it is written… Will improving health literacy help to create a better relationship between patients and pharma through having easier, and understandable, communications?

Then, will that help to improve the shared decicion making process?

Having a true understanding of what our diseases are, and how they affect us, will help them to understand our ‘needs’ to a much better level, the kind that brings us closer together and be able to communicate easier. This is my own opinion!

Decision making could become a ‘shared experience’ meaning patient involvement, and engagement, could become more ‘viable’ as well as successful. This is my own opinion!

Is this true? Does having a better understanding of disease awareness improve shared decision making?

Through learning to understand our diseases better, and how they affect us, it should develop a better understanding of the patient experience.

In my own opinion!! This means that learning about disease awareness, how to create a shared decision making experience through using a communicable language understood by both patients, and pharma, should improve the level of trust!

Considering the above… Would this help to bridge the gap between patients, and pharma, by improving their relationships enough to improve the level of ‘trust’?